Cargando…
Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last?
Delayed immune-related events (DIRE) occur after ≥90 days of discontinuation of immunotherapy. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes and is used frequently in the management of multiple cancers. Immunotherapy-related ad...
Autor principal: | Calle Sarmiento, Paola Michelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355134/ https://www.ncbi.nlm.nih.gov/pubmed/37476113 http://dx.doi.org/10.7759/cureus.40627 |
Ejemplares similares
-
Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023) -
The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman
por: Salman, Bushra, et al.
Publicado: (2023) -
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021) -
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)